Drug Profile
Research programme: curcumin analogues - Traverse Biosciences
Alternative Names: CMC 2.24; TRB N0224Latest Information Update: 25 Apr 2023
Price :
$50
*
At a glance
- Originator State University of New York at Stony Brook
- Developer The Feinstein Institute for Medical Research; Traverse Biosciences
- Class Small molecules
- Mechanism of Action Inflammation mediator inhibitors; Matrix metalloproteinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Neuroblastoma
- Research Osteoarthritis
Most Recent Events
- 25 Apr 2023 Early research in Osteoarthritis is still ongoing in USA (Traverse Biosciences pipeline, April 2023)
- 25 Apr 2023 Preclinical trial in Neuroblastoma is still ongoing in USA (Traverse Biosciences pipeline, April 2023)
- 20 Apr 2016 Preclinical trials in Neuroblastoma in USA (PO) prior to April 2016